Latest news and press releases about Kiora Pharmaceuticals, Inc. (KPRX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic candidate, KIO-301, is a groundbreaking small molecule undergoing Phase 1 clinical trials.
Price
| Price | $2.60 |
| Market Cap | $12M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.99 |
| EV / EBITDA | -0.38 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -63.39% |
| Return on Invested Capital | -53.16% |
| Return on Assets | -46.21% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACXP · ADIL · APRE · APVO · BCDA · CELZ · HCWB
Explore sector: Healthcare · Biotechnology
More sections of KPRX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks